Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide

I. M. Thompson, C. R. Spence, D. L. Lamm, N. R. Diluzio

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.

Original languageEnglish (US)
Pages (from-to)294-300
Number of pages7
JournalAmerican Journal of the Medical Sciences
Volume294
Issue number5
StatePublished - 1987

Fingerprint

Glucans
Cyclophosphamide
Urinary Bladder
Carcinoma
Transitional Cell Carcinoma
Tumor Burden
Neoplasms
Immunologic Adjuvants
Immunotherapy
Cell Wall
Saccharomyces cerevisiae
Drug Therapy
Mortality
Incidence
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thompson, I. M., Spence, C. R., Lamm, D. L., & Diluzio, N. R. (1987). Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide. American Journal of the Medical Sciences, 294(5), 294-300.

Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide. / Thompson, I. M.; Spence, C. R.; Lamm, D. L.; Diluzio, N. R.

In: American Journal of the Medical Sciences, Vol. 294, No. 5, 1987, p. 294-300.

Research output: Contribution to journalArticle

Thompson, IM, Spence, CR, Lamm, DL & Diluzio, NR 1987, 'Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide', American Journal of the Medical Sciences, vol. 294, no. 5, pp. 294-300.
Thompson, I. M. ; Spence, C. R. ; Lamm, D. L. ; Diluzio, N. R. / Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide. In: American Journal of the Medical Sciences. 1987 ; Vol. 294, No. 5. pp. 294-300.
@article{71d285f88d594854851df8644913bed8,
title = "Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide",
abstract = "Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.",
author = "Thompson, {I. M.} and Spence, {C. R.} and Lamm, {D. L.} and Diluzio, {N. R.}",
year = "1987",
language = "English (US)",
volume = "294",
pages = "294--300",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide

AU - Thompson, I. M.

AU - Spence, C. R.

AU - Lamm, D. L.

AU - Diluzio, N. R.

PY - 1987

Y1 - 1987

N2 - Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.

AB - Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.

UR - http://www.scopus.com/inward/record.url?scp=0023619601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023619601&partnerID=8YFLogxK

M3 - Article

C2 - 3425579

AN - SCOPUS:0023619601

VL - 294

SP - 294

EP - 300

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 5

ER -